论文部分内容阅读
目的探讨糖尿病下肢血管病变(Lower extremity arterial disease,LEAD)患者下肢血管256层螺旋CT血管造影(CT angiography,CTA)成像特点及发生危险因素。方法回顾性分析2型糖尿病150例的临床及下肢动脉256层CTA资料,分析糖尿病LEAD病变特点,比较LEAD与非LEAD一般资料差异,并对糖尿病LEAD相关危险因素进行Logistic回归分析。结果 256层CTA诊断LEAD112例,动脉狭窄程度Ⅰ级26例,Ⅱ级33例,Ⅲ级40例,Ⅳ级13例;狭窄节段血管1 156支,发生在髂总动脉89支,髂外动脉94支,髂内动脉85支,股总动脉76支,股浅动脉89支,股深动脉57支,腘动脉129支,胫前动脉165支,胫腓干77支,胫后动脉152支,腓动脉143支。LEAD组和非LEAD组性别、病程、收缩压(SBP)、舒张压(DBP)、餐后2h血糖(PBG2h)、糖化血红蛋白(HbA1C)、C反应蛋白(CRP)、低密度脂蛋白胆固醇(LDL-C)及同型半胱氨酸(Hcy)比较差异有统计学意义(P<0.05)。Logistic回归分析结果显示,HbA1C、SBP、CRP、Hcy及LDL-C与2型糖尿病LEAD明显相关。结论 256层CTA是一种简便、安全、准确的早期检出糖尿病LEAD的手段,糖尿病患者应综合管理血糖、血压、血脂等多种危险因素,以预防和延缓LEAD发生、发展。
Objective To investigate the imaging features and risk factors of lower extremity CT angiography (CTA) in lower extremity arterial disease (LEAD). Methods A retrospective analysis of 150 cases of type 2 diabetes mellitus clinical and lower extremity arterial 256 CTA data analysis of characteristics of LEAD lesions, LEAD and non-LEAD general data were compared, and the risk factors for diabetes LEAD logistic regression analysis. Results The 256-slice CTA was used to diagnose LEAD in 112 cases. The grade of arterial stenosis was Grade Ⅰ in 26 cases, Grade Ⅱ in 33 cases, Grade Ⅲ in 40 cases and Grade Ⅳ in 13 cases. The stenosis segment included 1 156 vessels, including 89 common iliac arteries, 94 branches, internal iliac artery 85, common femoral artery 76, superficial femoral artery 89, femoral artery 57, popliteal artery 129, anterior tibial artery 165, tibiofibular 77, 152 posterior tibial artery, The peroneal artery 143. Gender, duration of disease, SBP, DBP, PBG2h, HbA1C, C-reactive protein (CRP), LDL cholesterol -C) and homocysteine (Hcy) were significantly different (P <0.05). Logistic regression analysis showed that HbA1C, SBP, CRP, Hcy and LDL-C were significantly associated with LEAD in type 2 diabetes. Conclusion 256-layer CTA is a simple, safe and accurate method for early detection of LEAD. Diabetes patients should comprehensively manage various risk factors such as blood glucose, blood pressure and blood lipid to prevent and delay the occurrence and development of LEAD.